Petrozumab ( Perjeta® (brand name); pertuzumab (generic name) )

Immunotherapy

EMA Approved

Hospital use off-label in CRC 1 Clinical Trials

Description

Pertuzumab is primarily used in combination with trastuzumab and chemotherapy for the treatment of HER2-positive breast cancer. Its use in colorectal cancer (CRC) remains investigational, particularly in patients with HER2-amplified tumors where it may be combined with other targeted therapies.

Mechanism of Action

Petrozumab, also known as pertuzumab, is a monoclonal antibody that targets the HER2 receptor, inhibiting dimerization and downstream signaling pathways associated with cell proliferation.

Side Effects

Fever; neutropenia; thrombocytopenia; diarrhea; nausea

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05725200 Phase 2

Recruiting

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Norway

Quick Info

Brand Name	Perjeta® (brand name); pertuzumab (generic name)
Category	Immunotherapy
EMA Status	EMA Approved
Spain Access	Hospital use off-label in CRC
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Petrozumab (** Perjeta® (brand name); pertuzumab (generic name) **)